Drugs / Edecesertib
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04809623 | Sep 2021 → Oct 2022 | cutaneous lupus erythematosus | Gilead Sciences | Terminated | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT05629208 | Apr 2023 → Dec 2025 | cutaneous lupus erythematosus | Gilead Sciences | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Edecesertib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04809623 ↗ |
| Modality | Small molecule | — CHEMBL5095097 ↗ |
| Route | Oral | “Tablets administered orally” NCT05629208 ↗ |